Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,161 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01667419 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma(BRIM8) | completed | Phase 3 | 498 | Hoffmann-La RocheINDUSTRY | 29 | Jul 23, 2019 | clinicaltrials |
| NCT02069704 | Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | completed | Phase 1 | 142 | mAbxience Research S.L.INDUSTRY | 5 | Jul 23, 2019 |
| clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | completed | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 21 | Jul 16, 2019 | clinicaltrials |
| NCT01142674 | T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma | completed | — | 1,650 | Associazione Angela Serra per la ricerca sul cancroOTHER | 14 | Jul 8, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | terminated | Phase 3 | 143 | Alexion Pharmaceuticals, Inc.INDUSTRY | 18 | Jun 26, 2019 | clinicaltrials |
| NCT03721289 | Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients(PANORAMRETRO) | completed | — | 463 | AstraZenecaINDUSTRY | 4 | Jun 12, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | completed | Phase 2 | 152 | Hoffmann-La RocheINDUSTRY | 18 | Jun 3, 2019 | clinicaltrials |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | terminated | Phase 3 | 1,418 | Hoffmann-La RocheINDUSTRY | 29 | Apr 12, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | completed | Phase 3 | 222 | Incyte CorporationINDUSTRY | 18 | Mar 6, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT01633060 | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi(BELLE-3) | terminated | Phase 3 | 432 | Novartis PharmaceuticalsINDUSTRY | 22 | Jan 30, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer(BOLERO-1) | completed | Phase 3 | 719 | Novartis PharmaceuticalsINDUSTRY | 28 | Dec 19, 2018 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT03775798 | Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV. | unknown | — | 2,200 | Austral University, ArgentinaOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03775863 | AFP Model and Liver Transplantation. | completed | — | 1,200 | Austral University, ArgentinaOTHER | 2 | Dec 19, 2018 | clinicaltrials |
| NCT00974311 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy(AFFIRM) | completed | Phase 3 | 1,199 | PfizerINDUSTRY | 15 | Dec 11, 2018 | clinicaltrials |
| NCT00087022 | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | completed | Phase 3 | 864 | Heidelberg Pharma AGINDUSTRY | 4 | Nov 27, 2018 | clinicaltrials |
| NCT01861236 | Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina(FAST AR) | completed | — | 90 | Ferring PharmaceuticalsINDUSTRY | 1 | Oct 23, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT00683306 | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | approved for marketing | — | — | AstraZenecaINDUSTRY | 19 | Sep 13, 2018 | clinicaltrials |
| NCT02028494 | Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer(CAP7/7) | unknown | N/A | 350 | Latin American & Caribbean Society of Medical OncologyOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01026142 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | completed | Phase 3 | 452 | Hoffmann-La RocheINDUSTRY | 23 | Aug 14, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT03090139 | Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets | completed | — | 1,731 | TakedaINDUSTRY | 10 | Jun 26, 2018 | clinicaltrials |
| NCT01532102 | Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts | completed | Phase 1 / Phase 2 | 24 | Anaconda PharmaINDUSTRY | 2 | May 30, 2018 | clinicaltrials |
| NCT03048136 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer(CheckMate 955) | withdrawn | Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 5 | Apr 17, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT01137682 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly(PAOLA) | completed | Phase 3 | 198 | Novartis PharmaceuticalsINDUSTRY | 18 | Apr 5, 2018 | clinicaltrials |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | completed | Phase 3 | 322 | GlaxoSmithKlineINDUSTRY | 19 | Apr 5, 2018 | clinicaltrials |
| NCT00338286 | A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy | completed | Phase 3 | 2,098 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 19, 2018 | clinicaltrials |
| NCT03071848 | A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer | completed | — | 84 | Hoffmann-La RocheINDUSTRY | 1 | Mar 16, 2018 | clinicaltrials |
| NCT01345682 | LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 483 | Boehringer IngelheimINDUSTRY | 19 | Feb 15, 2018 | clinicaltrials |
| NCT00364351 | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | completed | Phase 3 | 1,574 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Jan 25, 2018 | clinicaltrials |
| NCT00950300 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | completed | Phase 3 | 596 | Hoffmann-La RocheINDUSTRY | 26 | Jan 23, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT03404752 | Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients. | unknown | Phase 3 | 120 | Gema Biotech S.A.INDUSTRY | 1 | Jan 19, 2018 | clinicaltrials |
| NCT02042144 | Safety and Effectiveness of Regorafenib(Correlate) | completed | — | 1,034 | BayerINDUSTRY | 13 | Jan 16, 2018 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials